Form 4: Entrada CFO Sells Shares for Tax Obligations
Insider Transaction Report
Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, sold 1,734 shares of common stock to cover tax withholding obligations related to RSU vesting.
Summary
- Kory James Wentworth, Chief Financial Officer of Entrada Therapeutics, Inc. (TRDA), disposed of 1,734 shares of common stock.
- The transaction occurred on September 2, 2025, at a weighted average price of $5.4302 per share, with prices ranging from $5.36 to $5.58.
- The shares were sold to cover tax withholding obligations associated with the vesting of previously granted Restricted Stock Units (RSUs).
- Following this transaction, Mr. Wentworth beneficially owns 118,936 shares of Entrada Therapeutics common stock.
Sentiment
Score: 5
Explanation: The transaction is a routine sale to cover tax obligations upon RSU vesting, which is a neutral event and does not indicate a change in management's outlook on the company or its operational performance.
Industry Context
This filing details a routine insider transaction for tax purposes, which is common for executives receiving equity compensation. It does not provide information directly related to broader industry trends or competitive positioning.
Stakeholder Impact
- Minimal direct impact on shareholders as it's a small, routine tax-related sale by an executive, not indicative of a change in company fundamentals or executive confidence.
Key Dates
| Date | Description |
|---|---|
| 09/02/2025 | Date of earliest transaction (sale of shares to cover tax withholding) |
| 09/04/2025 | Signature date of the reporting person's attorney-in-fact |
Recommendation
holdThis Form 4 filing details a routine, non-discretionary sale of shares by the CFO to cover tax obligations associated with RSU vesting. Such transactions are common and do not typically reflect a change in the executive's confidence in the company's future or its operational performance. Therefore, it provides no new information that would warrant a change in investment recommendation, suggesting a 'hold' position remains appropriate based solely on this filing.
Keywords
Entrada Therapeutics, TRDA, Kory James Wentworth, Chief Financial Officer, CFO, Insider Transaction, Form 4, Stock Sale, RSU Vesting, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.